Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733958 | 1.00 | KEAP1 (0.57) | KEAP1NFE2L2KMT2APLCG1ALDH1A1 | |
| SCHEMBL2734226 | 1.00 | KEAP1 (0.57) | KEAP1NFE2L2KMT2APLCG1ALDH1A1 | |
| SCHEMBL2733953 | 0.98 | KEAP1 (0.59) | KEAP1NFE2L2KMT2APLCG1ALDH1A1 | |
| SCHEMBL3683856 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL8778811 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL9099940 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL8778823 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL9102994 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL9099317 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL9101224 | 0.84 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | WISCONSIN MED COLLEGE INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8466130-B2 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | COLBY PHARMACEUTICAL COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2139522-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | Colby Pharmaceutical Company (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008109740-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | KEAP1 982/4885NFE2L2 144/4885KMT2A 3446/4885 |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | KEAP1 982/4885NFE2L2 144/4885KMT2A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.